Last edition
News about "D3 Bio "
D3 Bio Secures FDA IND Clearance for Two Oncology Programmes
The US FDA has cleared two Investigational New Drug (IND) applications from D3 Bio, paving the way for a phase I clinical trial of D3S-003 and a phase II combination study evaluating elisrasib (D3S-001) with D3S-002, marking a key step forward in the company’s oncology development pipeline.
D3 Bio | 23/01/2026 | By News Bureau | 321
D3 Bio has received FDA IND clearance to initiate a Phase I trial of its KRAS G12D inhibitor D3S-003 and a Phase II combination study targeting KRAS G12C-mutant lung cancer.
D3 Bio | 19/01/2026 | By News Bureau | 525
D3 Bio Secures USD 108 Million in Series B Financing to Advance Global Clinical Programmes
D3 Bio has raised USD 108 million in Series B financing to advance its global clinical programmes. The funds will support the Phase III pivotal trial of its lead asset, elisrasib (D3S-001), while also accelerating the development of the company’s broader pipeline of targeted and immuno-oncology therapies with first-in-class and best-in-class potential.
D3 Bio | 11/12/2025 | By Akanki | 206
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy